New Treatments Activated in Clinical Trial at Henry Ford Cancer Institute

In a global clinical trial, GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment), Henry Ford Cancer Institute is the first to activate two new treatments for glioblastoma. The GBM AGILE trial allows for global collaboration and has the potential to increase breakthroughs in the research and treatment for glioblastoma. This trial will eventually enroll patients at 35 sites in the United States, Canada, Europe, and China.

The two treatments tested in this trial are VAL-083 from Kintara Therapeutics, Inc.  and paxalisib from Kazia Therapeutics Limited. Both interventions are being tested in newly-diagnosed and recurrent glioblastoma.

Learn more about this innovative trial here.

Share this post

Share on facebook
Share on twitter
Share on pinterest
Share on email

Get the Latest from Brains for the Cure

Add your address to our mailing list to get monthly updates about progress in the fight against brain tumors, as well as new community opportunities.

Brains for the Cure is a program of the Head for the Cure Foundation, which is powered by the generous support of donors. Learn more about how you can join the fight.